DAFNA Capital Management LLC lifted its stake in shares of Galapagos NV (NASDAQ:GLPG) by 9.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 38,609 shares of the biotechnology company’s stock after purchasing an additional 3,250 shares during the quarter. Galapagos NV comprises 2.1% of DAFNA Capital Management LLC’s portfolio, making the stock its 11th largest position. DAFNA Capital Management LLC’s holdings in Galapagos NV were worth $2,954,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Federated Investors Inc. PA boosted its position in shares of Galapagos NV by 36.8% in the second quarter. Federated Investors Inc. PA now owns 1,364,600 shares of the biotechnology company’s stock worth $104,419,000 after buying an additional 366,800 shares during the period. Renaissance Technologies LLC boosted its position in shares of Galapagos NV by 49.5% in the second quarter. Renaissance Technologies LLC now owns 465,300 shares of the biotechnology company’s stock worth $35,605,000 after buying an additional 154,100 shares during the period. Wellington Management Group LLP boosted its position in shares of Galapagos NV by 9.5% in the first quarter. Wellington Management Group LLP now owns 458,088 shares of the biotechnology company’s stock worth $39,483,000 after buying an additional 39,729 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Galapagos NV by 0.6% in the second quarter. Goldman Sachs Group Inc. now owns 202,173 shares of the biotechnology company’s stock worth $15,471,000 after buying an additional 1,235 shares during the period. Finally, Williams Jones & Associates LLC boosted its position in shares of Galapagos NV by 2.9% in the second quarter. Williams Jones & Associates LLC now owns 91,317 shares of the biotechnology company’s stock worth $6,988,000 after buying an additional 2,535 shares during the period. Institutional investors and hedge funds own 23.62% of the company’s stock.

Galapagos NV (NASDAQ:GLPG) traded down 1.69% on Friday, reaching $101.55. 44,856 shares of the company traded hands. Galapagos NV has a 52-week low of $57.16 and a 52-week high of $104.12. The company’s market capitalization is $5.17 billion. The stock has a 50-day moving average of $101.61 and a 200 day moving average of $101.61.

WARNING: This piece of content was first posted by Marea Informative and is owned by of Marea Informative. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at http://www.mareainformativa.com/galapagos-nv-glpg-shares-bought-by-dafna-capital-management-llc/117543/.

A number of analysts recently issued reports on GLPG shares. Zacks Investment Research raised Galapagos NV from a “hold” rating to a “buy” rating and set a $86.00 price objective for the company in a research report on Friday, July 14th. Royal Bank Of Canada initiated coverage on Galapagos NV in a report on Thursday, September 14th. They set a “sector perform” rating and a $98.00 target price on the stock. Morgan Stanley restated an “overweight” rating and set a $123.00 target price (up from $92.00) on shares of Galapagos NV in a report on Friday, October 6th. BTIG Research reiterated a “buy” rating and issued a $98.00 price objective on shares of Galapagos NV in a research note on Thursday, July 20th. Finally, Nomura dropped their price objective on Galapagos NV from $108.00 to $121.00 and set a “buy” rating on the stock in a research note on Thursday, June 22nd. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $108.14.

About Galapagos NV

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Institutional Ownership by Quarter for Galapagos NV (NASDAQ:GLPG)

Receive News & Stock Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related stocks with our FREE daily email newsletter.